Gilead Sciences Settles Kickback Allegations for $202 Million

Gilead Sciences Settles Kickback Allegations for $202 Million

Gilead Sciences has reached a $202 million settlement with the U.S. government and various states over claims of illegal inducements to physicians for prescribing its costly HIV medications. This agreement, publicized by prosecutors on Tuesday, addresses allegations that Gilead offered monetary rewards through speaker programs to influence medical prescriptions.

These inducements took the form of honoraria, meals, and covered travel expenses for participating doctors at sponsored HIV Speaker Program events from 2011 to 2017, as per details from the U.S. Attorney's Office in Manhattan.

Through these actions, the company aimed to promote prescriptions of their drugs like Biktarvy, Stribild, Genvoya, Complera, Odefsey, and Descovy, leveraging financial incentives to gain favor from healthcare providers.

Such practices were found to be in violation of the U.S. Anti-Kickback Statute, leading to false claims submitted for payment by federal health programs, notably Medicare and Medicaid, thus improperly inflating reimbursements.

The schemes involved some healthcare providers prescribing these medications, resulting in substantial payments derived from these federally funded health plans for what were deemed compromised prescriptions.

An instance highlighted by the U.S. Attorney's Office mentioned a doctor who allegedly received over $300,000 as honoraria, which corresponded with writing prescriptions that implied government program payouts exceeding $6 million.

Acting U.S. officials underscored Gilead's protracted efforts to amplify its drug sales through such tactics, involving more than $20 million allocated towards speaker fees and additional millions on opulent meals, alcohol, and travel expenses, all intended to sway physician prescription behaviors.

The finalized settlement, consisting of nearly $177 million directed to the U.S. government and the remainder apportioned among various states, received judicial approval from Judge Paul Engelmayer in the Manhattan U.S. District Court on Monday.

Gilead representatives have yet to provide a formal response regarding these developments, as no comments were available at the time requested by CNBC.

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts